SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Marshall SE. Behçet's disease. Best Pract Res Clin Rheumatol 2004; 18: 291311.
  • 2
    Santos Lacomba M, Marcos Martin C, Gallardo Galera JM, Gomez Vidal MA, Collantes Estevez E, Ramirez Chamond R, et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res 2001; 33: 2515.
  • 3
    Pipitone N, Olivieri I, Cantini F, Triolo G, Salvarani C. New approaches in the treatment of Adamantiades-Behçet's disease. Curr Opin Rheumatol 2006; 18: 39.
  • 4
    International Study Group for Behçet's Disease. Evaluation of diagnostic (‘classification’) criteria in Behçet's disease: towards internationally agreed criteria. Br J Rheumatol 1992; 31: 299308.
  • 5
    Licata G, Pinto A, Tuttolomondo A, Banco A, Ciccia F, Ferrante A, et al. Anti-tumour necrosis factor alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behçet's syndrome. Ann Rheum Dis 2003; 62: 2801.
  • 6
    Ribi C, Sztajzel R, Delavelle J, Chizzolini C. Efficacy of TNF (alpha) blockade in cyclophosphamide resistant neuro-Behçet disease. J Neurol Neurosurg Psychiatry 2005; 76: 17335.
  • 7
    Sarwar H, McGrath H Jr, Espinoza LR. Successful treatment of long-standing neuro-Behçet's disease with infliximab. J Rheumatol 2005; 32: 1813.
  • 8
    Fujikawa K, Aratake K, Kawakami A, Aramaki T, Iwanaga N, Izumi Y, et al. Successful treatment of refractory neuro-Behçet's disease with infliximab: a case report to show its efficacy by magnetic resonance imaging, transcranial magnetic stimulation and cytokine profile. Ann Rheum Dis 2007; 66: 1367.